H20.829 Vogt-Koyanagi syndrome, unspecified eye

Name of the Condition

• Vogt-Koyanagi syndrome, unspecified eye

Summary

Vogt-Koyanagi syndrome is a rare, multisystem inflammatory disorder primarily affecting the eyes, skin, and central nervous system. It is characterized by uveitis (inflammation of the uveal tract), often accompanied by extraocular manifestations such as vitiligo, poliosis (whitening of hair), and auditory disturbances. The condition typically follows a relapsing-remitting course and may lead to vision-threatening complications if untreated.

Causes

The exact cause is not fully understood, but it is believed to involve an autoimmune response targeting melanin-containing cells in the body. Genetic predisposition and environmental triggers (e.g., infections) may contribute to disease onset. The immune-mediated attack on melanocytes in the uvea, skin, and inner ear is thought to drive the clinical manifestations.

Risk Factors

• Genetic susceptibility (e.g., HLA associations)
• Ethnicity (more common in individuals of Asian, Hispanic, or Native American descent)
• Prior viral infections (e.g., herpesviruses)
• Female gender (slight predominance)

Symptoms

• Eye redness, pain, or photophobia (due to uveitis)
• Blurred vision or floaters
• Vitiligo (depigmented skin patches)
• Poliosis (whitening of eyebrows, eyelashes, or scalp hair)
• Tinnitus or hearing loss
• Headache or meningismus (in severe cases)

Diagnosis

Diagnosis is based on clinical evaluation, including a detailed history and physical examination. Ophthalmologic assessment for uveitis, skin examination for vitiligo or poliosis, and auditory testing may be performed. Laboratory tests (e.g., HLA typing) or imaging may support the diagnosis, but no single test confirms the condition. A multidisciplinary approach is often required to evaluate systemic involvement.

Treatment Options

Treatment focuses on reducing inflammation and managing symptoms. Corticosteroids (topical, oral, or injectable) are commonly used to control uveitis. Immunosuppressive agents (e.g., methotrexate, azathioprine) may be prescribed for severe or refractory cases. Symptomatic treatments address extraocular manifestations, such as vitiligo or hearing loss. Regular monitoring by an ophthalmologist and other specialists is essential.

Prognosis and Follow-Up

Prognosis varies depending on the severity and timeliness of treatment. Early intervention can preserve vision and reduce systemic complications. The condition often follows a relapsing course, requiring long-term monitoring. Follow-up includes regular eye exams, skin assessments, and auditory evaluations to detect recurrence or progression.

Complications

• Permanent vision loss due to untreated uveitis
• Cataracts or glaucoma from chronic inflammation
• Progressive skin depigmentation
• Sensorineural hearing loss
• Neurologic involvement (e.g., meningitis)

Lifestyle & Prevention

• Protect eyes from UV light with sunglasses
• Manage stress, as it may trigger flares
• Avoid known environmental triggers (e.g., infections)
• Maintain regular follow-up with healthcare providers

When to Seek Professional Help

Seek immediate medical attention for sudden vision changes, severe eye pain, or new neurological symptoms (e.g., headache, confusion). Prompt evaluation is critical to prevent permanent damage.

Tips for Medical Coders

This code (H20.829) is specific to Vogt-Koyanagi syndrome affecting an unspecified eye. Documentation should clarify the absence of laterality (right/left) or specify if laterality is not documented. Ensure clinical notes support the diagnosis and exclude other uveitic conditions. Code assignment depends on the provider’s documentation of eye involvement.